Brainstorm Cell Therapeutics (BCLI) Stock Price, News & Analysis

Company Overview

Brainstorm Cell Therapeutics, trading on NASDAQ under the symbol BCLI, is a biotechnology company focused on the development and commercialization of innovative cell therapies for neurodegenerative diseases. Its lead investigational product, NurOwn, uses autologous mesenchymal stem cells (MSCs) engineered to secrete high levels of neurotrophic factors, aiming to protect and repair damaged neurons. The company’s proprietary platform seeks to address conditions with significant unmet medical needs, including amyotrophic lateral sclerosis (ALS), multiple sclerosis, Parkinson’s disease and Alzheimer’s disease.

The NurOwn process involves harvesting a patient’s own MSCs, expanding and differentiating the cells in a controlled laboratory setting, and then administering them back to the patient via intrathecal or intravenous infusion. Brainstorm has completed multiple clinical trials for ALS in the United States and is preparing for potential regulatory submissions. Preclinical research is under way to explore applications in additional neurological disorders, highlighting the platform’s versatility across a range of degenerative conditions.

Founded in 2000 and originally incorporated in Israel, Brainstorm Cell Therapeutics maintains research and manufacturing facilities in Ra’anana, Israel, along with a corporate office in New York. The company has built a global network of clinical collaborators and strategic partners to support its trials and future commercialization efforts. Brainstorm’s production capabilities adhere to Good Manufacturing Practice (GMP) standards, ensuring consistent quality and scalability of its cell therapy products.

Brainstorm is led by a management team of industry veterans with deep expertise in biotechnology, clinical development and regulatory affairs. The company’s scientific advisory board includes leading neurologists and stem cell researchers who guide its R&D strategy. By leveraging its cell therapy platform and fostering collaborative partnerships, Brainstorm Cell Therapeutics aims to bring new treatment options to patients affected by devastating neurodegenerative diseases.

Key Stats

• Today's Range: $1.18 to $1.26
• 50-Day Range: $1.06 to $1.36
• 52-Week Range: $0.72 to $6.45
• Volume: 193,219 shs
• Average Volume: 397,897 shs
• Market Capitalization: $11.82 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $30.00
• Consensus Rating: Buy

Brainstorm Cell Therapeutics Stock Analysis - MarketRank™

Brainstorm Cell Therapeutics scored higher than 88% of companies evaluated by MarketBeat, and ranked 183rd out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Brainstorm Cell Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Brainstorm Cell Therapeutics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Brainstorm Cell Therapeutics are expected to grow in the coming year, from ($3.01) to ($1.60) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Brainstorm Cell Therapeutics is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Brainstorm Cell Therapeutics is -0.36, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.51% of the float of Brainstorm Cell Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Brainstorm Cell Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Brainstorm Cell Therapeutics has recently decreased by 13.71%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Brainstorm Cell Therapeutics does not currently pay a dividend.

Dividend Growth

Brainstorm Cell Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.66

Percentage of Shares Shorted

7.51% of the float of Brainstorm Cell Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Brainstorm Cell Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Brainstorm Cell Therapeutics has recently decreased by 13.71%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: 0.32

News Sentiment

Brainstorm Cell Therapeutics has a news sentiment score of 0.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Brainstorm Cell Therapeutics this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for BCLI on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

MarketBeat Follows

4 people have added Brainstorm Cell Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Brainstorm Cell Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

11.15% of the stock of Brainstorm Cell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 14.33% of the stock of Brainstorm Cell Therapeutics is held by institutions.

BCLI Stock Analysis - Frequently Asked Questions

How have BCLI shares performed this year?

Brainstorm Cell Therapeutics' stock was trading at $2.27 at the beginning of 2025. Since then, BCLI shares have decreased by 47.4% and is now trading at $1.1950.

How were Brainstorm Cell Therapeutics' earnings last quarter?

Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) posted its quarterly earnings data on Thursday, May, 15th. The biotechnology company reported ($0.45) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by $0.07.
Read the conference call transcript.

When did Brainstorm Cell Therapeutics' stock split?

Shares of Brainstorm Cell Therapeutics reverse split on the morning of Tuesday, October 1st 2024.The 1-15 reverse split was announced on Thursday, September 26th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 30th 2024. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

How do I buy shares of Brainstorm Cell Therapeutics?

Shares of BCLI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Brainstorm Cell Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Brainstorm Cell Therapeutics investors own include CocaCola (KO), Organovo (ONVO), Cardium Therapeutics (CRXM), Anavex Life Sciences (AVXL), Sangamo Therapeutics (SGMO), Protalix BioTherapeutics (PLX) and Isoray (ISR).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/10/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BCLI
• CIK: 1137883
• Web: www.brainstorm-cell.com
• Phone: (201) 488-0460
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Brainstorm Cell Therapeutics: $30.00
• High Price Target: $30.00
• Low Price Target: $30.00
• Potential Upside/Downside: +2,319.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.36)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.62 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -519.50%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.21
• Quick Ratio: 0.21

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.36) per share
• Price / Book: -0.91

Miscellaneous

• Outstanding Shares: 9,840,000
• Free Float: 8,742,000
• Market Cap: $12.20 million
• Optionable: Optionable
• Beta: 0.22